Codiak presents preclinical results for modular vaccine platform

By The Science Advisory Board staff writers

May 15, 2020 -- Codiak BioSciences released new preclinical data on its engEx platform at the American Society of Gene and Cell Therapy annual meeting.

Specifically, the company highlighted the use of its exoVACC vaccine platform to direct tropism for multiple cell lines in vitro and in vivo. The engEx platform loads exosomes with various therapeutic targets to alter tropism and target specific cells.

Codiak is developing the platform to target multiple pathways throughout the body to treat various types of cancer and enhance immune responses with an array of antigens. The modular platform is designed to incorporate multiple complex antigens, adjuvants, targeting ligands, and immune costimulatory molecules within a single exosome.

Avrobio moves forward with gene therapy candidate
Avrobio released preclinical data for AVR-RD-03, lentiviral gene therapy for Pompe disease, at the American Society of Gene and Cell Therapy annual meeting...

Copyright © 2020 scienceboard.net


Conferences
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Laboratory Products Association Annual Meeting
October 1-4
Scottsdale, Arizona United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter